JINLING PHARM.(SZ:000919)2022-12-07 09:34Group 1: Company Strategy and Development - The company's development strategy focuses on leveraging comparative advantages to create two profitable platforms: pharmaceutical production and medical services, aiming for both to achieve equal profitability within 3-5 years [2] - The acquisition of Anqing Hospital is progressing, with the company actively negotiating with local government and stakeholders [2][3] - The company has no current plans for incentives for the core management team of the hospitals [3] Group 2: Hospital Acquisition and Market Overview - Anqing Hospital is undergoing restructuring, and the company is in discussions regarding the acquisition of its equity [2] - The company plans to invest no more than 140 million RMB to acquire the controlling stake in Anqing Petrochemical Hospital, which has 562 operational beds and specializes in burn and plastic surgery [7][9] - Anqing City has a population of 6.2 million, with an average annual disposable income of over 22,200 RMB for urban residents [6] Group 3: Operational Insights and Future Plans - The company currently operates two hospitals and recognizes the need to focus on developing a professional talent pool for sustainable growth [4] - The company has no specific timeline or quantity planning for future hospital layouts [3] - The company is committed to both expanding its main business through acquisitions and considering divestment of underperforming assets [10] Group 4: Financial Performance and Hospital Metrics - Nanjing Drum Tower Hospital, affiliated with Nanjing University Medical School, has 2,500 beds and served over 2.6 million outpatient visits in 2013 [8] - Anqing Hospital has 29 clinical and medical technology departments, with key specialties in burn and plastic surgery, as well as nephrology and otolaryngology [6][7]